The startup develops a vessel tracking technology that continuously monitors intracranial pressure in patients with abnormal and traumatic brain conditions using advanced optics and proprietary artificial intelligence. This technology provides instant assessments, enabling physicians to make informed clinical decisions based on real-time data.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Elevated intracranial pressure (ICP) is a life-threatening condition arising from traumatic brain injury, stroke, and other conditions. Current methods for monitoring ICP are invasive, costly, and carry a risk of infection and hemorrhage. Detecting elevated ICP can be difficult because its symptoms often resemble those of other less serious diseases.
Solution
StatuManu ICP is developing ICP Tracker, a software-as-a-service (SaaS) medical device that provides non-invasive measurement and monitoring of intracranial pressure. ICP Tracker analyzes fundus images to detect variations in ICP, providing immediate assessment and continuous monitoring. The device measures the diameter of blood vessels in the fundus of the eye, using deep learning methods to estimate changes in ICP. The non-invasive nature of ICP Tracker allows for quick investigation and diagnosis of conditions with suspected elevated intracranial pressure, without the need for surgical intervention.
Target Audience
The primary target audience includes healthcare professionals (HCPs) attending to adult patients with suspected changes in ICP, neurosurgical units, and emergency care units.
Features
- Non-invasive intracranial pressure assessment using fundus images
- Software-as-a-service (SaaS) delivery model
- Deep learning algorithms for analyzing fundus images and detecting ICP variations
- Continuous monitoring of ICP changes over time
- Measurement of blood vessel diameter in the eye to estimate ICP
- Intended for use with adult patients (18+) with suspected changes in ICP
- Designed to be used in conjunction with existing clinical procedures, not as a stand-alone diagnostic tool